Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: Data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Nicholas David James*, Melissa R. Spears, Noel W. Clarke, David P. Dearnaley, Johann S. De Bono, Joanna Gale, John Hetherington, Peter J. Hoskin, Robert J. Jones, Robert Laing, Jason F. Lester, Duncan McLaren, Christopher C. Parker, Mahesh K.B. Parmar, Alastair W.S. Ritchie, J. Martin Russell, Räto T. Strebel, George N. Thalmann, Malcolm D. Mason, Matthew R. Sydes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa - the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE) - includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort. Objective Describe survival outcomes, along with current treatment standards and factors associated with prognosis, to inform future trial design in this patient group. Design, setting, and participants STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who were recruited between October 2005 and January 2014. Outcome measurements and statistical analysis Overall survival (OS) and failure-free survival (FFS) were reported by primary disease characteristics using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (CIs) were derived from multivariate Cox models. Results and limitations A cohort of 917 men with newly diagnosed M1 disease was recruited to the control arm in the specified interval. Median follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 34-373). Most men (n = 574; 62%) had bone-only metastases, whereas 237 (26%) had both bone and soft tissue metastases; soft tissue metastasis was found mainly in distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% CI, 68-76). Survival time was influenced by performance status, age, Gleason score, and metastases distribution. Median survival after FFS event was 22 mo. Trial eligibility criteria meant men were younger and fitter than general PCa population. Conclusions Survival remains disappointing in men presenting with M1 disease who are started on only long-term ADT, despite active treatments being available at first failure of ADT. Importantly, men with M1 disease now spend the majority of their remaining life in a state of castration-resistant relapse. Patient summary Results from this control arm cohort found survival is relatively short and highly influenced by patient age, fitness, and where prostate cancer has spread in the body.

Original languageEnglish
Pages (from-to)1028-1038
Number of pages11
JournalEuropean Urology
Volume67
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Control arm cohort
  • Hormone-naïve
  • Metastatic
  • Natural history
  • Prognostic factors
  • Prospective data
  • Prostate cancer
  • Survival
  • Time to progression

Fingerprint

Dive into the research topics of 'Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: Data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)'. Together they form a unique fingerprint.

Cite this